# David R. Webb

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-r-webb/

## Facts

| Field | Value |
| --- | --- |
| Citations | 14,251 |
| Field | Diabetes Treatment and Management |
| h-index | 58 |
| i10-index | 213 |
| Last Known Institution | University of Leicester |
| OpenAlex ID | https://openalex.org/A5068804442 |
| ORCID iD | 0000-0002-3932-3339 |
| Works | 443 |

## Researcher papers

- [Type 2 diabetes](https://scholariq.org/papers/type-2-diabetes-3/)
- [Regulation of the immune response by prostaglandins](https://scholariq.org/papers/regulation-of-the-immune-response-by-prostaglandins/)
- [Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective](https://scholariq.org/papers/pathophysiology-of-type-1-and-type-2-diabetes-mellitus-a-90-year-perspective/)
- [Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis](https://scholariq.org/papers/efficacy-and-safety-of-sodium-glucose-co-transporter-2-inhibitors-in-type-2/)
- [Efficacy and safety of glucagon‐like peptide‐1 receptor agonists in type 2 diabetes: <scp>A</scp> systematic review and mixed‐treatment comparison analysis](https://scholariq.org/papers/efficacy-and-safety-of-glucagon-like-peptide-1-receptor-agonists-in-type-2/)
- [Discovery of Alogliptin:  A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV](https://scholariq.org/papers/discovery-of-alogliptin-a-potent-selective-bioavailable-and-efficacious/)
- [Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure.](https://scholariq.org/papers/impaired-microvascular-dilatation-and-capillary-rarefaction-in-young-adults-with/)
- [Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy](https://scholariq.org/papers/targeting-the-p27-e3-ligase-scfskp2-results-in-p27-and-skp2-mediated-cell-cycle/)
- [Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation.](https://scholariq.org/papers/carbenoxolone-increases-hepatic-insulin-sensitivity-in-man-a-novel-role-for-11/)
- [An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme](https://scholariq.org/papers/an-allosteric-inhibitor-of-the-human-cdc34-ubiquitin-conjugating-enzyme/)
- [The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials](https://scholariq.org/papers/the-effects-of-weight-lowering-pharmacotherapies-on-physical-activity-function/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Kidney Stones and Urolithiasis Treatments](https://scholariq.org/topics/kidney-stones-and-urolithiasis-treatments/)
- [Pediatric Urology and Nephrology Studies](https://scholariq.org/topics/pediatric-urology-and-nephrology-studies/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

## Researcher university

- [University of Leicester](https://scholariq.org/institutions/university-of-leicester/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.